BRAF V600 Mutation clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase I, First-In-Human, open label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with documented BRAF V600 mutation and locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in Part A, or in combination with cobimetinib (Cotellic®) in Part B in adult patients who also have documented progressive disease or intolerance to previous combination treatment of BRAF and MEK inhibitors. A "3+3" design will be used to determine MTD and RP2D.
San Francisco, California and other locations
Our lead scientists for BRAF V600 Mutation research studies include Katy Tsai.